$ALNY

Yvonne L. Greenstreet

Alnylam Pharmaceuticals

CEO • Since 2022 • Health Care

📊 CEO Reputation Score

FY2025 vs FY2024 · Source: SEC EDGAR filings

96/100

Blend of this company's year-over-year free-cash-flow and profit improvement, each ranked as a percentile against every scored company in the three indexes.

Free cash flow: −$43M → $465M (+1192.7% YoY) — fiscal 2025 vs fiscal 2024
Profit (net income): −$278M → $314M (+212.8% YoY) — fiscal 2025 vs fiscal 2024

How this score works · Nasdaq-100 reputation leaderboard

Overview

Yvonne L. Greenstreet is the ceo of Alnylam Pharmaceuticals since 2022. Alnylam Pharmaceuticals is a Health Care company, and one of the 100 companies in the Nasdaq-100 — every one of which is profiled on this site.

Leadership

Yvonne holds the chief executive role at Alnylam Pharmaceuticals with the title CEO — in post since 2022. This page is the concise leadership record for Alnylam Pharmaceuticals in the Nasdaq-100 CEO index; the site's fully researched long-form profiles (career timelines, education, achievements, setbacks, philosophy and sourced quotes) currently cover the index's ten largest companies, and this entry will be expanded in the same format.

At a Glance

Sector: Health Care
Ticker: $ALNY
CEO since: 2022
Index: Nasdaq-100 (#4 of 100)